About the Webinar
Cancer is comprised of heterogeneous cell populations, and research is increasingly becoming dependent on the ability to isolate rare cells, both enriched populations as well as individual, single cells. Employing advanced molecular and cytogenetic technologies to analyze isolated rare cells, such as circulating tumor cells, provides a unique opportunity to interrogate the cancer biomarkers.
About the Presenter
Dr. Wang is a veteran in molecular diagnostics and has extensive and critical expertise in the development of cancer diagnostic technologies, including the first FDA-approved circulating tumor cell (CTC) technology, CellSearch. Prior to joining Celsee Diagnostics, he was Vice President, Molecular Probes, at Ventana Medical Systems/Roche, and Executive Director, R&D at Veridex, an oncology molecular and cellular diagnostic business of J&J. Dr. Wang has broad experience in identifying molecular markers, and developing and validating companion molecular assays. He earned his Ph.D. in Molecular Biology from Cornell University and his B.S. in Biochemistry from Beijing University.